MAPT and Alzheimer disease: Future work should determine to what extent substantia nigra tau PET uptake could serve as a biomarker of dopaminergic neuron loss across clinical phenotypes, which could meet the current need for novel biomarkers of dopaminergic loss and Alzheimer’s disease co-pathology.54